OBJECTIVES The goal of this study was to assess the safety and tolerability of omecamtiv mecarbil treatment during symptom-limited exercise in patients with ischemic cardiomyopathy and angina. These patients may have increased vulnerability to prolongation of the systolic ejection time.
O mecamtiv mecarbil (formerly CK-1827452
and AMG 423) is a selective, small molecule activator of cardiac myosin that binds to the catalytic domain of myosin and increases the transition rate of myosin into the actin-bound force-generating state without affecting cardiac myocyte intracellular calcium (1) . In healthy subjects and in patients with stable heart failure, infusions of omecamtiv mecarbil resulted in statistically significant, doserelated, and concentration-related increases in systolic ejection time associated with increases in indices of left ventricular (LV) systolic function such as stroke volume, fractional shortening, and ejection fraction (2, 3) . No consistent pattern of adverse events (AEs) was observed in patients who were tolerant of drug infusion. In both healthy subjects and patients with heart failure, the dose-limiting effect of omecamtiv mecarbil was myocardial ischemia. This occurred in some patients at plasma concentrations >1,200 ng/ml and was likely due to excessive prolongation of the systolic ejection time, reducing the time for coronary perfusion during diastole. Because heart rate, coronary blood flow, and myocardial oxygen demand increase while the overall duration of the cardiac cycle shortens, factors that may increase susceptibility to ischemia when systolic ejection time is increased include coronary artery disease or exercise.
Our goal was to understand the effects of exercise on the safety and tolerability of omecamtiv mecarbil in a relevant patient population as a prelude to chronic dosing. The present study was designed to evaluate omecamtiv mecarbil in patients with ischemic cardiomyopathy and angina in a controlled, wellmonitored setting by using symptom-limited exercise during intravenous (IV) infusions of omecamtiv mecarbil. The doses of omecamtiv mecarbil were selected to produce plasma drug concentrations associated with increases in systolic ejection time and LV systolic function (2) . An additional goal of the study was to obtain the first pharmacokinetic and tolerability data in patients with heart failure after oral dosing to steady state. Table S1 ) (4).
METHODS
Exclusion criteria included acute myocarditis; clinically significant restrictive, constrictive, or hypertrophic obstructive cardiomyopathy; clinically significant congenital heart disease; systolic blood pressure >160 mm Hg documented on $3 occasions separated by 10 min; levels of troponin I or T or CPK-MB greater than the upper limit of normal (ULN) within 6 weeks of screening and up to randomization; severe aortic or mitral stenosis; acute coronary syndrome, transient ischemic attack, or revascularization within 6 weeks of screening; significant comorbid conditions that would limit treadmill exercise; renal or hepatic impairment; receipt of an investigational drug or device within 30 days or 5 half-lives before randomization; weight >120 kg; body temperature
>38
C; any laboratory abnormality that would preclude participation in the study; or previous treatment with omecamtiv mecarbil.
STUDY DESIGN. Two sequential cohorts of patients were enrolled ( Figure 1 ). Before randomization, patients had to complete 2 separate screening ETTs (ETT1 and ETT2) administered at least 24 h apart, achieving $4 min of a Modified Naughton Exercise
Protocol on both tests (Online Methods). Baseline ETT performance was defined as the shorter of the 2 exercise durations recorded during the screening ETTs.
Patients in each cohort were randomly assigned in a 2:1 ratio to receive an IV infusion of omecamtiv in the omecamtiv mecarbil arms were dosed to target plasma levels of w295 ng/ml in cohort 1 (24 mg/h for 2 h followed by 6 mg/h for 18 h) and w550 ng/ml in cohort 2 (48 mg/h for 2 h followed by 11 mg/h for 18 h).
Patients who tolerated the IV infusion then selfadministered omecamtiv mecarbil orally (immediate release; 12.5 mg and 25 mg for cohorts 1 and 2, respectively) or placebo orally 3 times daily for 7 days.
Patients had a follow-up visit 6 to 14 days after the last oral dose. There were no exercise tests during or after oral dosing.
In each cohort, patients were assigned to treatment via central randomization by an independent vendor.
An unblinded site pharmacist prepared the study medications and provided them to blinded site staff according to the randomization system assignment. Baseline demographic and clinical characteristics were similar among patients receiving placebo or omecamtiv mecarbil ( Table 1, Online Table S2 ). All patients were white, and most (80%) were men; their mean age was 63.4 years. Eleven patients (11.7%) stopped one of the baseline exercise tests conducted before study drug infusion (ETT1 or ETT2) because of angina (none in cohort 1; 4 on placebo; 7 on omecamtiv mecarbil in cohort 2).
PRIMARY AND SECONDARY SAFETY ENDPOINTS. In the placebo arm, 1 patient (3.4%) stopped ETT3
(during infusion) at a stage earlier than baseline because of angina while none did so in the omecamtiv mecarbil arm at either dose ( Table 2, Online Table S3 ).
Seven patients (1 taking placebo; 4 taking omecamtiv mecarbil in cohort 1; 2 taking omecamtiv mecarbil in cohort 2) stopped ETT3 for any reason at a stage earlier than baseline ( Table 2 ). There were 9 patients who also stopped at least one of the baseline ETTs (ETT1 and/or ETT2) because of angina; 7 of these 9 patients stopped both baseline
ETTs because of angina. During ETT3, the same 9 Values are mean AE SD, range, or n (%). *Cohort 1: Omecamtiv mecarbil infused at 24 mg/h for 2 h followed by 6 mg/h for 18 h. Patients who tolerated the infusion then received omecamtiv mecarbil 12.5 mg orally 3 times daily for 7 days. †Cohort 2: Omecamtiv mecarbil infused at 48 mg/h for 2 h followed by 11 mg/h for 18 h. Patients who tolerated the infusion then received omecamtiv mecarbil 25 mg orally 3 times daily for 7 days. ‡Baseline ETT was the shorter of the screening ETTs (ETT1 or ETT2).
ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin II receptor blocker; BMI ¼ body mass index; ETT ¼ exercise tolerance test; LVDD ¼ left ventricular end-diastolic dimension; LVEF ¼ left ventricular ejection fraction; MI ¼ myocardial infarction; SBP ¼ systolic blood pressure.
patients (2 in the placebo group; 7 in the omecamtiv mecarbil group in cohort 2) stopped again because of angina ( Table 2 ). In 3 of these 9 patients, the duration of ETT3 was shorter than the baseline ETT (1 patient in the placebo group; 2 in the omecamtiv mecarbil group in cohort 2). The exercise stage at which each of these 9 patients stopped ETT3 was the same stage at which their baseline ETT was stopped, and hence they did not contribute to the primary endpoint.
Exercise time during ETT3 compared with baseline increased in all treatment groups ( Table 2) Values are n (%) or mean AE SD. *Cohort 1: Omecamtiv mecarbil infused at 24 mg/h for 2 h followed by 6 mg/h for 18 h. Patients who tolerated the infusion then received omecamtiv mecarbil 12.5 mg orally 3 times daily for 7 days. †Cohort 2: Omecamtiv mecarbil infused at 48 mg/h for 2 h followed by 11 mg/h for 18 h. Patients who tolerated the infusion then received omecamtiv mecarbil 25 mg orally 3 times daily for 7 days. ‡Patients were not considered to have electrocardiographs interpretable for ST-segment analysis if they had baseline STsegment depression $1 mm, left bundle branch block or right bundle branch block, or ventricular pacing or if they were receiving digoxin. §Values for 2 patients with 1-mm ST-segment depression during ETT-3. kValue for 1 patient with 1-mm ST-segment depression during ETT-3.
T R E A T M E N T-E M E R G E N T A E
NA ¼ not applicable; other abbreviation as in Table 1 .
heart rate, respiratory rate, and oxygen saturation) or cardiac enzymes (troponin I, CPK-MB, and total creatine kinase) for any of the treatment groups were observed. Systolic blood pressure and heart rate data throughout the study are shown in Online Tables S5   and S6 . Overall, few patients had detectable or elevated levels of troponin I (Online Table S7 ) or CPK-MB above the ULN (Online Table S8 ) at any time during the study. Before study drug infusion, 1 patient in the placebo group and 1 patient in cohort 1 had detectable or elevated troponin I levels at screening, and 1 patient in the placebo group had detectable or elevated troponin I levels before and after ETT1. Two patients taking omecamtiv mecarbil had troponin I results that were just above the ULN after study drug infusion following ETT3: peak troponin I levels were 0.13 mg/l (ULN <0.11 mg/l) for a patient in cohort 1 and 1.1 mg/l (ULN <1.0 mg/l) for a patient in cohort 2. There were no other clinical signs or symptoms of ischemia in these 2 patients. C max levels were 344 AE 265 ng/ml and 708 AE 268 ng/ml in cohorts 1 and 2, respectively. Time to C max was similar between doses ( Table 4) . Mean plasma concentrations 1 h after the last oral dose were 74 ng/ml for cohort 1 and 208 ng/ml for cohort 2.
DISCUSSION
Increasing cardiac contractility would seem to be a rational approach to treating patients with systolic heart failure. However, inotropic drugs increase the risk of ischemia, arrhythmias, and death, and this risk has limited their utility in treating acute and chronic heart failure (6-10). Currently available inotropic drugs increase cardiac contractility indirectly by increasing cardiac myocyte intracellular calcium concentration (11) . Another approach to increasing cardiac contractility by directly activating the sarcomere with a cardiac myosin activator may overcome the limitations of the currently available inotropic drugs (12) .
Omecamtiv mecarbil is a novel, direct cardiac myosin activator that increases cardiac contractility and may become an important therapy for heart failure patients with systolic dysfunction. The echocardiographic hallmark for the pharmacodynamic activity of omecamtiv mecarbil is an increase in the systolic ejection time that is highly correlated with omecamtiv mecarbil plasma concentration (2,3).
Because the majority of coronary blood flow occurs during diastole, this effect of omecamtiv mecarbil could reduce the time for myocardial perfusion. Thus, it was critical to evaluate omecamtiv mecarbil in patients with ischemic cardiomyopathy and angina during exercise in a well-controlled and monitored setting.
The present study was designed to provide an indication of the safety and tolerability of omecamtiv mecarbil in ambulatory patients with chronic heart Troponin I levels were abnormal in 2 patients after exercise; in each case, the levels were just above the upper laboratory reference limit and occurred in the absence of other clinical signs or symptoms of cardiac ischemia. The background rate of detectable troponin after exercise testing in this patient population is not well established, but was approximately 10% in 2 small studies (13, 14) . Given the number of patients studied, our findings do not rule out the possibility that increases in troponin I might occur in some heart failure patients with coronary disease during exercise while receiving omecamtiv mecarbil treatment, but they do indicate that the occurrence of this event is likely to be low. The use of a high-sensitivity troponin assay in this study might have provided additional insights into the development of ischemia in this population during exercise.
STUDY LIMITATIONS. Although the present study provides the first evaluation of omecamtiv mecarbil in heart failure patients under nonsedentary conditions, it has some important limitations. No hypothesis was formally tested, and the sample size was therefore empirically determined to be sufficient to provide an adequate assessment of the tolerability of the 2 target omecamtiv mecarbil plasma levels during symptom-limited exercise tolerance in patients with ischemic cardiomyopathy and angina.
In addition, the sample size was too small to assess the effect on exercise time, and thus either a positive or negative effect on exercise duration could Values are n (%). *Cohort 1: Omecamtiv mecarbil infused at 24 mg/h for 2 h followed by 6 mg/h for 18 h. Patients who tolerated the infusion then received omecamtiv mecarbil 12.5 mg orally 3 times daily for 7 days. †Cohort 2: Omecamtiv mecarbil infused at 48 mg/h for 2 h followed by 11 mg/h for 18 h. Patients who tolerated the infusion then received omecamtiv mecarbil 25 mg orally 3 times daily for 7 days.
AE ¼ adverse event; CPK ¼ creatine phosphokinase. Values are mean AE SD. *Cohort 1: Omecamtiv mecarbil infused at 24 mg/h for 2 h followed by 6 mg/h for 18 h. †Cohort 2: Omecamtiv mecarbil infused at 48 mg/h for 2 h followed by 11 mg/h for 18 h.
AUClast ¼ area under the plasma concentration-time curve from time 0 to the time of last quantifiable plasma concentration; Cmax ¼ maximum plasma concentration; IV ¼ intravenous; Tmax ¼ time to maximum plasma concentration.
not be established. The study did not formally assess the effect of omecamtiv mecarbil on inducible ischemia or chest pain, and the angina burden of the study population was not thoroughly characterized.
The majority of ECGs in the enrolled population were noninterpretable for ischemia, which is common in patients with heart failure, and only a minority had angina while performing exercise in this study. Confining enrollment to heart failure patients with evidence of reproducible exercise- 
